Introduction
CD154, also referred to as CD40 Ligand (CD40L), gp39, and TRAP, is a member of the tumor necrosis factor (TNF) ligand superfamily that plays a critical role in the modulation of humoral and cellular immunity.
1 CD154 is a type II membrane protein originally thought to be restricted to activated T cells. 1,2 CD154 mediates immunomodulatory effects, via binding to its cognate receptor CD40, which is widely expressed on cells of the adaptive immune compartment including B cells, monocytes/macrophages, and dendritic cells. 3 CD154/CD40 interaction is essential for the activation, maturation, and development of the high-affinity humoral response, as well as enhancing antigen presentation leading to efficient T cell function. 1, 2, 4 The importance of the CD154/CD40 axis on adaptive immune responses is evident by the immunocompromised phenotype observed in patients with genetic CD154 deficiency. 5 An emerging role for the CD154/CD40 axis is the modulation of inflammation. Elevated serum levels of a biologically active, soluble form of CD154 (sCD154) is observed in patients with a variety of chronic and acute inflammatory diseases including SLE, type I and II diabetes, glomerular nephritis and coronary heart disease. 2, [6] [7] [8] [9] [10] Soluble CD154 is shown to trigger proinflammatory and prothrombotic activity in major vessels via ligation of CD40 in smooth muscle and endothelium. 11- 13 Mach and colleges showed a direct role for CD154 on atheroma development and altering phenotype. [14] [15] [16] Additional studies implicate CD154 as a key modulator of other inflammatory diseases such as SLE and diabetes. Interruption of CD154 activity via immunosuppressive and antibody-based therapies have been shown to improve symptoms and slow disease progression.
10, [17] [18] [19] [20] The emerging role for CD154 in vascular inflammation makes understanding the source and regulation of CD154 an important link to the design of possible anti-inflammatory therapies. While CD154 was traditionally associated with activated T cells, subsequent studies showed platelets, anucleate cells traditionally associated with hemostasis, were an abundant source of membrane-bound and soluble CD154.
21,22
Because CD154 expression was believed to be restricted to T cells, the vast majority of studies have focused on understanding the transient, inducible CD154 expression in the only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From context of T cells activation. A consensus of CD154 regulation studies in both primary T cells and T cell lines demonstrate a requirement of activation induced T cell-associated nuclear factor of activated T cells (NFAT) transcription factors. [23] [24] [25] NFATs are a family of calcineurin-dependent transcription factors essential for the T cell activation-induced regulation of several other cytokines imperative for T cell growth and function including
Interleukin -2 (IL-2), Fas ligand, CD154, and TNFα. [24] [25] [26] [27] [28] [29] The central role of NFAT in the modulation of T cell-specific cytokines such as IL-2 and CD154 is the basis for the immunosuppressive activity of the calcineurin inhibitors cyclosporine A (CsA) and FK506 and has lead to the use of such compounds for the treatment of autoimmune inflammatory disorders such as SLE. 17, 23, [30] [31] [32] Given the abundance of platelets, the discovery that platelet-associated CD154 can mediate prothrombotic and proinflammatory effects on vascular cells strongly implicates a role for platelets in onset and progression of inflammatory diseases. The present study represents the first investigation into the regulation of CD154 in platelet precursor cells, megakaryocytes. We observed that CD154 expression is restricted to the megakaryocyte lineage in non-lymphoid hematopoietic cells. Furthermore, our promoter analysis indicates that differentiation-enhanced transcription of CD154 is at least in part, mediated via NFAT, transcription factors associated with activated T cells. The demonstration that CsA suppresses CD154 expression in megakaryocytes has potential clinical implications in that a novel and abundant source of CD154 can be potentially modulated.
Materials and methods
Cell Lines and reagents. K562, Meg-01, CMK, HL-60, Jurkat, and Hela cell lines were purchased from ATCC (Manassas, VA) and were routinely maintained in RPMI 1640, supplemented with 10% heat-inactivated FCS, 10mM L-glutamine, and 100µg/ml Pen- hypothesized that platelets acquire CD154 from megakaryocytes during thrombogenesis.
Reinforcing this hypothesis is the previous observation that platelets express full-length, only.
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Human CD34+ hematopoietic progenitor cells were differentiated in vitro to mature megakaryocytes using culture conditions described in Materials and Methods. After 14
days, approximately 70% of the differentiated cells expressed CD41, a cell surface integrin whose expression is restricted to megakaryocytes (data not shown). These data indicate CD154 is constitutively expressed in primary mouse megakaryocytes and appears to be associated with culture-derived differentiated cells bearing the megakaryocyte phenotype.
To verify lineage specific expression and to better characterize regulation in megakaryocytes, we assessed CD154 mRNA expression in a panel of human leukemia cell lines possessing the capacity to undergo megakaryocyte-specific differentiation via chronic PKC activation. Cell lines displaying bipotential, myeloblastic phenotype (K562), pre-megakaryoblastic phenotype (Meg-01) and early megakaryocyte phenotype (CMK) were assessed for CD154 mRNA and protein expression before and after induction of megakaryocyte differentiation using 4 day exposure in the presence of 10 -8
M PMA. As a control for non-specific, differentiation-mediated expression, CD154
expression was also assessed in HL-60 before and after macrophage differentiation with only.
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of the megakaryocytes. To confirm that CD154 expression is megakaryocyte-specific, we exploited the ability of K562 to differentiate to an erythroblast lineage via exposure to hemin (100 mM), or to megakaryocyticdifferentiation via exposure to PMA. The data in figure 4A indicates CD154 expression is suppressed after erythroblastic-specific differentiation. While the PKC agonist PMA is well established as an inducer of megakaryocyte differentiation in some myeloid and premegakaryocyte cell lines, it is evident that the observed CD154 gene induction could be an artifact of a non-specific inducer. For this reason, we wanted to determine expression kinetics and to distinguish between differentiation-driven versus PMA-driven expression of CD154. For this, CMK cells were assessed for CD154 mRNA expression at various time points after PMA exposure and then at 48 hours after removal of PMA stimulation.
As a control for mature megakaryocyte differentiation, cells were monitored for polyploidy by observation by light microscopy and counting of multinucleated cells per given field. Figure 4B shows that CD154 mRNA levels gradually increase over 96 hours, corresponding with more cells displaying a mature megakaryocyte phenotype. Moreover, both % polyploid cells and CD154 mRNA levels continued to increase 48 hours after removal of PMA. Figure 4C For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From promoter activity is enhanced in megakaryocytes. For these experiments, the 5' regulatory region of CD154, -1800 to +65 bp relative to the transcription start site was isolated and cloned into the pGL3 basic luciferase reporter vector. The resulting vector (p1800CD154-luc) was transfected into untreated and 96 hour PMA-differentiated CMK, Meg-01, and K562 cells. Figure 5A shows enhanced transcriptional activity of the CD154 promoter in the MK-differentiated cells. These data show enhanced transcriptional activity of the CD154 promoter in the megakaryocytes.
In order to elucidate the mechanism of increased transcriptional activity, the amount of the 5' flanking region required for megakaryocyte-associated transcription was determined using 5' flank deletion constructs. Figure 5B and NFAT elements as revealed by a motif search of the TRANSFAC database (Matinspector). To functionally assess the GATA and the distal and proximal NFAT elements on megakaryocyte-specific CD154 transcription, mutational analysis was performed by generating -391 bp reporter constructs with point mutations to the GATA site or the NFAT sites. The data in figure 6 shows that mutational deletion of the distal NFAT site but not the GATA-1 element nor the proximal NFAT site diminished transcriptional activity. These data indicate that unlike T cell-specific CD154 expression, only the distal NFAT element is required for megakaryocyte-specific promoter activity.
To verify NFAT protein occupancy of the distal NFAT site, EMSA were used to examine the in vitro binding of nuclear protein, isolated from untreated and differentiated CMK cells, to an oligonucleotide probe containing the distal NFAT and the 20 flanking 
35-41
Based on the abundant expression of CD154 expression by activated platelets, the current study characterized the CD154 regulation in platelet precursor cells; megakaryocytes.
We show that CD154 is differentially expressed in various in vitro hematopoietic cell lines and primary human and mouse hematopoietic precursor cells. Specifically, CD154
mRNA is highly expressed in primary mouse bone marrow-derived CD41+ cells versus CD34+ precursors and CD41+ depleted bone marrow cells. Further, CD154 expression is enhanced from undetectable levels in both mouse and human primary CD34+ stem cell precursors, to high-level expression following cytokine-induced megakaryocyte-specific differentiation. Our observations in primary megakaryocytes were recapitulated in various hematopoietic cell lines by demonstrating that CD154 expression is enhanced in cell lines either representative of the megakaryocyte lineage (CMK and Meg-01), or after megakaryocyte-specific differentiation of a multipotient precursor cell line (K562). We only.
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Our observations that enhanced CD154 expression and promoter activity appears associated specifically with a mature megakaryocyte phenotype originally led us to hypothesize that CD154 was potentially regulated via GATA and Ets-1, families of transcriptional regulators shown to be key mediators of megakaryocyte-restricted genes including gpIIb, gpIX and PF-4. only.
